eLearningClasses.com

Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

NEW YORK, Feb. 15, 2019 — In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BCE, Inc. (NYSE:BCE), Nektar Therapeutics (NASDAQ:NKTR), Hormel Foods Corporation (NYSE:HRL), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), MongoDB, Inc. (NASDAQ:MDB), and Regal Beloit Corporation (NYSE:RBC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

BCE DOWNLOAD: https://Fundamental-Markets.com/register/?so=BCE NKTR DOWNLOAD: https://Fundamental-Markets.com/register/?so=NKTR HRL DOWNLOAD: https://Fundamental-Markets.com/register/?so=HRL ENTA DOWNLOAD: https://Fundamental-Markets.com/register/?so=ENTA MDB DOWNLOAD: https://Fundamental-Markets.com/register/?so=MDB RBC DOWNLOAD: https://Fundamental-Markets.com/register/?so=RBC

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine BCE, Inc. (NYSE:BCE), Nektar Therapeutics (NASDAQ:NKTR), Hormel Foods Corporation (NYSE:HRL), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), MongoDB, Inc. (NASDAQ:MDB), and Regal Beloit Corporation (NYSE:RBC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

—————————————–

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 13th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

—————————————–

BCE, INC. (BCE) REPORT OVERVIEW

BCE’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, BCE reported revenue of $4,498.26MM vs $4,530.48MM (down 0.71%) and analysts estimated basic earnings per share $0.69 vs $0.69 (down 0.16%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, BCE reported revenue of $17,525.44MM vs $16,402.19MM (up 6.85%) and analysts estimated basic earnings per share $2.41 vs $2.52 (down 4.30%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.63. The estimated EPS forecast for the next fiscal year is $2.79 and is expected to report on February 6th, 2020.

To read the full BCE, Inc. (BCE) report, download it here: https://Fundamental-Markets.com/register/?so=BCE

—————————————–

NEKTAR THERAPEUTICS (NKTR) REPORT OVERVIEW

Nektar Therapeutics’ Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Nektar Therapeutics reported revenue of $27.76MM vs $152.93MM (down 81.85%) and analysts estimated basic earnings per share -$0.56 vs $0.39. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Nektar Therapeutics reported revenue of $307.71MM vs $165.44MM (up 86.00%) and analysts estimated basic earnings per share -$0.62 vs -$1.10. Analysts expect earnings to be released on March 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$1.49 and is expected to report on March 7th, 2019.

To read the full Nektar Therapeutics (NKTR) report, download it here: https://Fundamental-Markets.com/register/?so=NKTR

—————————————–

HORMEL FOODS CORPORATION (HRL) REPORT OVERVIEW

Hormel Foods’ Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Hormel Foods reported revenue of $2,524.70MM vs $2,492.61MM (up 1.29%) and analysts estimated basic earnings per share $0.49 vs $0.41 (up 19.51%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Hormel Foods reported revenue of $9,545.70MM vs $9,167.52MM (up 4.13%) and analysts estimated basic earnings per share $1.91 vs $1.60 (up 19.38%). Analysts expect earnings to be released on February 21st, 2019. The report will be for the fiscal period ending January 31st, 2019. Reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $1.98 and is expected to report on November 19th, 2019.

To read the full Hormel Foods Corporation (HRL) report, download it here: https://Fundamental-Markets.com/register/?so=HRL

—————————————–

ENANTA PHARMACEUTICALS, INC. (ENTA) REPORT OVERVIEW

Enanta Pharmaceuticals’ Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Enanta Pharmaceuticals reported revenue of $69.89MM vs $38.11MM (up 83.38%) and basic earnings per share $1.34 vs $0.61 (up 119.67%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, Enanta Pharmaceuticals reported revenue of $206.63MM vs $102.81MM (up 100.97%) and analysts estimated basic earnings per share $3.74 vs $0.93 (up 302.15%). Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.61. The estimated EPS forecast for the next fiscal year is -$1.04 and is expected to report on November 25th, 2019.

To read the full Enanta Pharmaceuticals, Inc. (ENTA) report, download it here: https://Fundamental-Markets.com/register/?so=ENTA

—————————————–

MONGODB, INC. (MDB) REPORT OVERVIEW

MongoDB’s Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, MongoDB reported revenue of $64.99MM vs $41.49MM (up 56.64%) and analysts estimated basic earnings per share -$0.59 vs -$1.39. For the twelve months ended January 31st, 2018 vs January 31st, 2017, MongoDB reported revenue of $154.52MM vs $101.36MM (up 52.45%) and analysts estimated basic earnings per share -$4.06 vs -$7.10. Analysts expect earnings to be released on March 12th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was -$0.40. The estimated EPS forecast for the next fiscal year is -$2.38 and is expected to report on March 12th, 2019.

To read the full MongoDB, Inc. (MDB) report, download it here: https://Fundamental-Markets.com/register/?so=MDB

—————————————–

REGAL BELOIT CORPORATION (RBC) REPORT OVERVIEW

Regal Beloit’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Regal Beloit reported revenue of $925.40MM vs $856.90MM (up 7.99%) and analysts estimated basic earnings per share $1.18 vs $1.40 (down 15.71%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Regal Beloit reported revenue of $3,360.30MM vs $3,224.50MM (up 4.21%) and analysts estimated basic earnings per share $4.78 vs $4.55 (up 5.05%). Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.34. The estimated EPS forecast for the next fiscal year is $6.90 and is expected to report on February 3rd, 2020.

To read the full Regal Beloit Corporation (RBC) report, download it here: https://Fundamental-Markets.com/register/?so=RBC

—————————————–

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected]

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: [email protected]

© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.